PSTV Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 5.49%

Insider Buying (Last 12 Months): $82,744.90

Insider Selling (Last 12 Months): $0.00

Plus Therapeutics Insider Trading History Chart

Plus Therapeutics Share Price & Price History

^$0.77

▼ -0.1151 (-12.93%)

As of 04/3/2025 05:00 PM ET

Days: 30 | 90 | 365

Plus Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2024	Richard J Hawkins	Director	Buy	4,000	$1.50	$6,000.00	15,188
9/11/2024	Howard Clowes	Director	Buy	5,000	$1.34	$6,700.00	26,497
9/10/2024	Andrew John Hugh Sims	CFO	Buy	4,098	$1.27	$5,204.46	9,815
9/10/2024	Marc H Hedrick	CEO	Buy	8,000	$1.23	$9,840.00	20,425
5/8/2024	Andrew John Hugh Sims	CFO	Buy	4,902	$2.04	$10,000.08	5,717
5/8/2024	Howard Clowes	Director	Buy	9,804	$2.04	$20,000.16	21,497
5/8/2024	Marc H Hedrick	CEO	Buy	12,255	$2.04	$25,000.20	12,425
11/20/2023	Marc H Hedrick	CEO	Sell	2,068	$1.96	$4,053.28	170
11/15/2023	Robert P. Lenk	Director	Buy	1,000	$1.77	$1,770.00	24,160
11/13/2023	Robert P. Lenk	Director	Buy	4,000	$1.43	$5,720.00	23,160
11/10/2023	Robert P. Lenk	Director	Buy	2,000	$1.45	$2,900.00	19,160
11/8/2023	Robert P. Lenk	Director	Buy	5,000	$1.65	$8,250.00	12,961
11/6/2023	Robert P. Lenk	Director	Buy	1,395	$1.50	$2,092.50	1,961
9/13/2023	Howard Clowes	Director	Buy	6,993	$1.43	$9,999.99	11,693
9/11/2023	Greg Petersen	Director	Buy	20,000	$1.70	$34,000.00	24,166
6/6/2023	Howard Clowes	Director	Buy	1,000	$3.98	$3,980.00	4,700
5/3/2023	Howard Clowes	Director	Buy	2,500	$3.64	$9,100.00	3,700
3/3/2023	Richard J Hawkins	Director	Buy	0	$15,000.00	$0.00
6/15/2022	Marc H Hedrick	CEO	Buy	333	$9.75	$3,246.75	2,238
6/2/2022	Howard Clowes	Director	Buy	1,000	$8.55	$8,550.00	1,200
4/26/2022	Andrew John Hugh Sims	CFO	Buy	200	$10.05	$2,010.00	815
4/26/2022	Marc H Hedrick	CEO	Buy	333	$10.35	$3,446.55	1,738

See Full Table

SEC Filings (Institutional Ownership Changes) for Plus Therapeutics (NASDAQ:PSTV)

3.28% of Plus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Plus Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/7/2024	AIGH Capital Management LLC	568,681	$0.84M	0.3%	N/A	9.977%
11/15/2022	Parkman Healthcare Partners LLC	1,325,025	$0.59M	0.2%	-13.6%	3.943%
8/8/2022	Otter Creek Advisors LLC	330,168	$0.18M	0.1%	+293.5%	1.465%
5/13/2022	Parkman Healthcare Partners LLC	1,526,316	$1.53M	0.4%	N/A	6.875%
5/9/2022	Otter Creek Advisors LLC	83,901	$84K	0.0%	N/A	0.378%
11/9/2021	BlackRock Inc.	128,323	$0.25M	0.0%	-19.7%	0.835%
9/17/2021	Virtu Financial LLC	76,187	$0.20M	0.0%	N/A	0.630%
8/16/2021	State Street Corp	34,214	$88K	0.0%	N/A	0.283%
8/13/2021	Renaissance Technologies LLC	17,607	$45K	0.0%	N/A	0.146%
8/13/2021	Northern Trust Corp	40,524	$0.10M	0.0%	N/A	0.335%
8/13/2021	Geode Capital Management LLC	130,793	$0.33M	0.0%	N/A	1.082%
8/13/2021	Vanguard Group Inc.	712,847	$1.83M	0.0%	+824.7%	5.897%
8/12/2021	Dimensional Fund Advisors LP	68,430	$0.18M	0.0%	N/A	0.566%
8/11/2021	Susquehanna Fundamental Investments LLC	13,033	$33K	0.0%	N/A	0.108%
2/24/2021	Virtu Financial LLC	18,318	$37K	0.0%	-16.5%	0.383%
2/10/2021	Renaissance Technologies LLC	106,100	$0.21M	0.0%	+202.7%	2.220%

Data available starting January 2016

See Full Table

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Today's Range

Now: $0.77

$0.75

$0.86

50 Day Range

MA: $1.08

$0.30

$1.57

52 Week Range

Now: $0.77

$0.24

$2.67

Volume

1,155,929 shs

Average Volume

3,962,091 shs

Market Capitalization

$4.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Who are the company insiders with the largest holdings of Plus Therapeutics?: Plus Therapeutics' top insider investors include:
Howard Clowes (Director)
Greg Petersen (Director)
Robert P Lenk (Director)
Marc H Hedrick (CEO)
Richard J Hawkins (Director)
Andrew John Hugh Macintyr Sims (CFO)
Learn More about top insider investors at Plus Therapeutics.